Risk factors
Connect Biopharma Holdings (CNTB) risk factors
Item 1A of every Connect Biopharma Holdings Ltd. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
110 risks, 11 new, 13 dropped, 23 reworded since the prior year. New risks focus on funding rademikibart, Simcere-related Renminbi transfers, regulatory conditions, reimbursement, and patient enrollment.
Filed Mar 31, 2026 - FY2024 10-K risk factors
112 risks. Clinical-stage biopharmaceutical company dependent on a single lead product candidate, rademikibart, with heavy operations and trial exposure in the U.S. and China.
Filed Mar 31, 2025